Research programme: P-type ATPase agonists- Centre for Drug Design and Discovery
Latest Information Update: 28 Oct 2026
At a glance
- Originator Centre for Drug Design and Discovery
- Class Antiparkinsonians
- Mechanism of Action Adenosine triphosphatase stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Oct 2026 No recent reports of development identified for research development in Parkinson's-disease in Belgium
- 28 Sep 2022 Research programme: P-type ATPase agonists- Centre for Drug Design and Discovery is available for licensing as of 21 Sep 2022. https://www.cd3.be/collaboration
- 21 Sep 2022 Early research in Parkinson's disease in Belgium (unspecified route) (Centre for Drug Design and Discovery website, September 2022)